Clinical development of bempedoic acid: phase 2 and phase 3 clinical trials
Clin Investig Arterioscler. 2021 May:33 Suppl 1:58-64.
doi: 10.1016/j.arteri.2021.02.005.
[Article in
English,
Spanish]
Affiliations
- 1 Servicio de Cardiología, Hospital Quirón Salud Bizkaia.
- 2 Unidad de Lípidos y Riesgo Vascular, Servicio de Medicina Interna,Hospital Universitario de Bellvitge-Idibell, Universidad de Barcelona, CIBEROBN, Fundación para la investigación y prevención de las enfermedades cardiovasculares (Fipec), España. Electronic address: xpinto@bellvitgehospital.cat.
Abstract
We review all the phase II and III studies carried out with bempedoic acid at the dose of 180mg, alone or in combination with different lipid-lowering drugs and in different subgroups of patients that unequivocally show the efficacy and safety of the drug. We point out some of the potential advantages of its use in clinical practice in patients with statin intolerance and the efficacy in reducing LDL-c when combined with statins, and with statins and ezetimibe, as well as in reducing inflammation markers pending the results of the CV Clear Outcomes trial that will end in 2022.
Keywords:
Acido bempedoico; Bempedoic acid; Fármacos hipolipemiantes; Hipercolesterolemia; Hypercholesterolemia; Lipid-lowering drugs; Tratamiento; Treatment.
Copyright © 2021 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Cholesterol, LDL / blood
-
Clinical Trials, Phase II as Topic
-
Clinical Trials, Phase III as Topic
-
Dicarboxylic Acids / administration & dosage*
-
Dicarboxylic Acids / adverse effects
-
Drug Development
-
Drug Therapy, Combination
-
Ezetimibe / administration & dosage
-
Fatty Acids / administration & dosage*
-
Fatty Acids / adverse effects
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
-
Hypercholesterolemia / drug therapy*
-
Hypolipidemic Agents / administration & dosage*
-
Hypolipidemic Agents / adverse effects
-
Inflammation / drug therapy
-
Inflammation / pathology
Substances
-
Cholesterol, LDL
-
Dicarboxylic Acids
-
Fatty Acids
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Hypolipidemic Agents
-
8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
-
Ezetimibe